PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15172781

Thalidomide.

Michael E Franks·Gordon R Macpherson·William D Figg
View original source ↗Export metadata ↓

Abstract

Despite its history as a human teratogen, thalidomide is emerging as a treatment for cancer and inflammatory diseases. Although the evolution of its clinical application could not have been predicted from the tragedy associated with its misuse in the past, its history serves as a lesson in drug development that underscores the need to understand the molecular pharmacology of a compound's activity, including associated toxicities. Here, we summarise the applications for thalidomide with an emphasis on clinical trials published over the past 10 years, and consider our knowledge of the molecular pharmacology of the drug in the context of clinical trial data, attempting to provide a mechanism-guided understanding of its activity.

Explore related subjects

Clinical Trials as TopicGastrointestinal DiseasesHIV InfectionsHumansNeoplasmsRheumatic DiseasesSkin DiseasesThalidomideJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Michael E Franks, Gordon R Macpherson, William D Figg. 2004-05-29. Thalidomide.. https://doi.org/10.1016/s0140-6736(04)16308-3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Power analyses for correlations from clustered study designs.

Power analysis constitutes an important component of modern clinical trials and research studies. Although a variety of methods and software packages are available, almost all of them are focused on regression models, with little attention paid to correlation analysis. However, the latter is arguably a simpler and more appropriate approach for modelling concurrent events, especially in psychosocial research. In this paper, we discuss power and sample size estimation for correlation analysis arising from clustered study designs. Our approach is based on the asymptotic distribution of correlated Pearson-type estimates. Although this asymptotic distribution is easy to use in data analysis, the presence of a large number of parameters creates a major problem for power analysis due to the lack of real data to estimate them. By introducing a surrogacy-type assumption, we show that all nuisance parameters can be eliminated, making it possible to perform power analysis based only on the parameters of interest. Simulation results suggest that power and sample size estimates obtained under the proposed approach are robust to this assumption.

Clinical Trials as Topic↗
PubMed2006

A comparison of stratified and adjusted trend tests for binomial proportions.

For the problem of testing for a monotonic trend between an ordinal exposure and a binary response while controlling for categorical cofactors, we derived stratified and adjusted versions of two single contrast tests. Using simulations, we compared their statistical properties to those of the commonly used stratified Mantel-extension trend (MET) test. All tests had high power in case of monotonic relationships between exposure and response. In case of non-monotonic relationships, the stratified and adjusted contrast tests were markedly less powerful than the stratified MET-test particularly for five exposure levels, a favourable feature when the aim is to test for the existence of a monotonic dose-response relationship. These results are illustrated by an example.

Clinical Trials as Topic↗